Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 191

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 191
---
, general and administrative expenses (2)         (346)                        —     
  Total operating expenses                                 (346)                        —     
  Net income (loss) from distribution agreements           —                            —     
  Impairment of intangible assets                          —                            —     
  Operating income (loss)                                  (131)                        —     
  Financial income                                         —                            —     
  Financial expenses                                       —                            —     
  Net financial income (loss)                              —                            —     
  Net income (loss) before tax                             (131)                        —     
  Income tax expense                                       —                            —     
  Net income (loss) from discontinued operations           (131)                        —     

(1)Research and development expenses. Research and development expenses relating to Lumoxiti discontinued operations are nil for the years ended December 31, 2022 and 2023, respectively.

(2)Selling, general and administrative expenses. Selling, general and administrative expenses relating to Lumoxiti discontinued operations amounted to €0.3 million and are nil for the years ended December 31, 2022 and 2023, respectively. For the year ended December 31, 2022, these expenses mainly consisted of remaining transition costs.

Critical Accounting Policies and Significant Judgments and Estimates

The Company's consolidated financial statements are prepared in accordance with IFRS. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the facts and circumstances. The actual value of the Company's assets, liabilities and shareholders’ equity, as well as its income and expenses, could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted. See Note 2 to the Company's consolidated financial statements included under "Item 18. Financial Statements" of this Annual Report.

The Company believes that the most significant management judgments and assumptions in the preparation of its consolidated financial statements are described below.

Accounting for collaboration and licensing arrangements

To date, the Company's revenue has been generated primarily from payments received in relation to research, collaboration and licensing agreements signed with pharmaceutical companies. These contracts generally provide for components such as upfront payments, milestone payments upon reaching certain predetermined development objectives, research and development funding, as well as payment of royalties on future sales of products.

Non-refundable upfront payments are deferred and recognized as revenue over the period Innate is engaged to deliver services to the third party